期刊
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
卷 6, 期 3, 页码 203-213出版社
AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jbn.2010.1119
关键词
Molecular Imaging; Molecular MRI; Magnetic Nanoparticles; Superparamagnetic Iron Oxide Nanoparticles; Gadolinium Contrast Agents; Molecular Biomarkers; Molecular Targeting
The development of molecular imaging technologies represents the opportunity to differentiate tissues based upon their metabolic and functional activity rather than structural and anatomic characteristics. The goal of molecular imaging is to reveal the pathophysiology underlying the observed anatomy and to diagnose disease based upon early biochemical processes. Detection of pathologic biomarkers can lead to early recognition of diseases, better therapeutic management, and improved monitoring for recurrence. Among the current clinical imaging modalities, MRI is uniquely suited for molecular imaging applications, offering a non-invasive means to obtain both anatomic and metabolic/functional information with high spatial and temporal resolution. Site-specific MRI contrast agents have been developed to target biologic processes that occur early in the development of diseases such as atherosclerotic plaques, tumor angiogenesis, and disease specific biosignatures. Furthermore, early disease recognition, prompting therapeutic intervention and drug delivery evaluation are possible using targeted contrast agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据